Margaret Keegan is Chief Executive Officer of Precision Medicine Group, which includes Precision AQ, for next-gen commercialization services and Precision for Medicine, a global CRO and lab services provider.
An industry luminary, Margaret has held executive leadership roles at large pharmaceutical and leading life sciences companies. Most recently, Margaret served as Operating Partner at Linden Capital Partners, where she evaluated opportunities across the sector, including providers of clinical research, pharmaceutical and commercial services. Prior to joining Linden Capital Partners, Margaret was the Executive Vice President, Chief Operating Officer at PRA Health Sciences, where she held sole responsibility for managing the business operations through the sale of the business to ICON plc. Earlier, Margaret spent over a decade at IQVIA, where she held roles of increasing responsibility, including President – Clinical Development, responsible for global clinical trials and President, Data Management, Biostatistics, Central Monitoring, Safety and Regulatory. Margaret launched her career in life sciences at GlaxoSmithKline.
Margaret holds a B.Sc. with First Class Honours in Mathematics from the University of Strathclyde and is a Chartered Statistician with the Institute of Statisticians, United Kingdom.
